Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Cheryl P. Ferrufino"'
Autor:
Olalekan O. Oluwole, Markqayne D. Ray, Richard M. Zur, Cheryl P. Ferrufino, Brett Doble, Anik R. Patel, S. Pinar Bilir
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionNovel therapies for 3L+ relapsed/refractory (r/r) follicular lymphoma (FL) have been approved recently by the US Food and Drug Administration including anti-CD19 CAR-T therapies such as axicabtagene ciloleucel (axi-cel) and CD20 × CD3 T-
Externí odkaz:
https://doaj.org/article/0bf9658a2eb640f7b7c7528ac49a045b
Autor:
Vamshi Ruthwik Anupindi, Sorin J. Brull, Diana L. Arper, Cheryl P. Ferrufino, Lori D. Bash, Amit D. Raval
Publikováno v:
Journal of clinical anesthesia. 66
Complete reversal of neuromuscular blockade (NMB) is important for patient safety and prognosis following surgical procedures involving NMB agents (NMBAs). Published evidence on the epidemiology and consequences of residual neuromuscular blockade (rN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::970ba51ac39bccf835b2d766cc2c82cc
https://pubmed.ncbi.nlm.nih.gov/32585565
https://pubmed.ncbi.nlm.nih.gov/32585565
Autor:
Susan Boklage, Cheryl P Ferrufino, Clare Proudfoot, Wenhui Wei, Chieh-I Chen, J. Munakata, Andreas Kuznik
Publikováno v:
ClinicoEconomics and Outcomes Research. 10:805-819
Cheryl P Ferrufino,1 Julie Munakata,1 Wenhui Wei,2 Clare Proudfoot,3 Andreas Kuznik,4 Susan H Boklage,4 Chieh-I Chen4 1IQVIA, Fairfax, VA, USA; 2Sanofi, Bridgewater, NJ, USA; 3Sanofi, Guildford, UK; 4Regeneron Pharmaceuticals, Inc., Tarrytown, NY,USA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eabd67f7244ab9342504dc54fa7af7f
https://doi.org/10.2147/ceor.s163829
https://doi.org/10.2147/ceor.s163829
Autor:
Cheryl P Ferrufino, Julie Munakata, Wenhui Wei, Clare Proudfoot, Andreas Kuznik, Susan Boklage, Chieh-I Chen
Publikováno v:
ClinicoEconomics and Outcomes Research: CEOR
Objective To estimate the 5-year budget impact (BI) on a US health plan of introducing sarilumab – a human immunoglobulin G1 anti-IL-6 receptor α monoclonal antibody – as combination treatment with conventional synthetic disease-modifying antirh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f74da89195f022fdd1876d9328e35b7
http://europepmc.org/articles/PMC6336131
http://europepmc.org/articles/PMC6336131
Autor:
Jeffrey E Carter, H Amani, Damien W Carter, Kevin N Foster, John A Griswold, William L Hickerson, James H Holmes, Samuel W Jones, General Surgery, Anjay Khandelwal, Nicole M Kopari, Jeffrey S Litt, Alisa Savetamal, Jeffrey W Shupp, Rajiv Sood, Cheryl P Ferrufino, Pratyusha Vadagam, Stacey Kowal, Tom Walsh, Jeremiah Sparks
Publikováno v:
Journal of Burn Care & Research. 42:S153-S154
Introduction Real-world data is observational data gathered outside of the experimental setting from diverse sources which is analyzed to produce real-world evidence. To better understand the impact of burn center treatment patterns, a national sampl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78b54329444473e6e4e07aaafc3d1896
https://doi.org/10.1093/jbcr/irab032.253
https://doi.org/10.1093/jbcr/irab032.253
Publikováno v:
Journal of Burn Care & Research. 41:S115-S115
Introduction Treatment pathways in burn care are typically determined based on burn center (BC) and patient characteristics, although decisions may be influenced by anecdotal experience, personal preference, and hospital policies/purchasing decisions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8246f05f03c65d25c0d9a32351333a20
https://doi.org/10.1093/jbcr/iraa024.178
https://doi.org/10.1093/jbcr/iraa024.178
Publikováno v:
ClinicoEconomics and Outcomes Research: CEOR
Christine L Baker,1 Yao Ding,2 Cheryl P Ferrufino,2 Stacey Kowal,2 Jenen Tan,3 Prasun Subedi1 1Patient & Health Impact, Pfizer, Inc, New York, NY, USA; 2Health Economics & Outcomes Research, Real World Evidence Solutions, IQVIA, Fairfax, VA, USA; 3IQ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a154e68704db90e5a850eda15bcd0869
https://www.dovepress.com/a-cost-benefit-analysis-of-smoking-cessation-prescription-coverage-fro-peer-reviewed-article-CEOR
https://www.dovepress.com/a-cost-benefit-analysis-of-smoking-cessation-prescription-coverage-fro-peer-reviewed-article-CEOR
Autor:
Thanh-Nghia, Nguyen, Jeffrey, Trocio, Stacey, Kowal, Cheryl P, Ferrufino, Julie, Munakata, Dell, South
Publikováno v:
American healthdrug benefits. 9(9)
Health management is becoming increasingly complex, given a range of care options and the need to balance costs and quality. The ability to measure and understand drivers of costs is critical for healthcare organizations to effectively manage their p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d6928812071896f58b21c33f70cba836
https://pubmed.ncbi.nlm.nih.gov/28465775
https://pubmed.ncbi.nlm.nih.gov/28465775
Publikováno v:
Drug Safety. 35:629-644
Background: Obesity is a serious and rapidly growing health problem worldwide. Few therapies are available beyond diet, exercise and bariatric surgery. A previously approved medication, sibutramine, has been withdrawn from the market due to concerns
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bdd123e81cfde524941cbd0f15678b3
https://doi.org/10.1007/bf03261960
https://doi.org/10.1007/bf03261960
Autor:
Linda Chen, S. Kowal, Spencer B. Cherry, Cheryl P Ferrufino, Richard H. Chapman, Craig S. Roberts
Publikováno v:
Value in Health. 13(6):685-694
Objective We sought to compare the cost-effectiveness of different interventions that have been shown to improve adherence with antihypertensive and lipid-lowering therapy, by combining a burden of nonadherence model framework with literature-based d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51ac26208561c8acf5418665f99f0410